Informed Prostate Cancer Patient Support

Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole genome sequencing with histopathological features | bioRxiv

Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy - Beck - The Prostate - Wiley Online Library onlinelibrary.wiley.com Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy Jérémie Beck 24–30 minutes 1 INTRODUCTION Noncurative treatment of advanced prostate cancer (PCa) relies mainly on the use of androgen deprivation therapy (ADT). Despite ADT efficacy, PCa will eventually progress to castration-resistance prostate cancer (CRPC) but many will remain dependent on steroids for growth. This explains why the combination of ADT with androgen receptor axis-targeted therapies (ARAT; apalutamide, darolutamide, enzalutamide, abiraterone acetate) delayed time to progression and death in metastatic PCa

Cancer Research UK - Science blog news.cancerresearchuk.org Can cancer cells communicate? Tim Gunn 10–13 minutes Breast cancer cells might use bioelectric signals to influence their behaviour. NIH / CC BY-NC 2.0 You’re electric. Not in a charge-via-USB, keep-away-from-water kind of way – but electric all the same. We all are. Electricity is a big part of how our bodies work. Our cells need to keep certain chemicals inside and push others out, which gives each one a voltage, like a tiny battery. That gives our cells the power to do some incredible things. The ones in our hearts, brains and nervous systems use bioelectricity on their outer layers – in precise patterns of blinks, waves and buzzes – to flash signals and messages through the body. We think and feel in lightning storms – which makes sense, because thoughts and feelings come like lightning storms sometimes. Dr Amanda Fou

Patterns of Failure in Men with Radiorecurrent Prostate Cancer: A Post-Hoc Analysis of Three Prospective Ga-68-PSMA PET/CT Imaging Trials - International Journal of Radiation Oncology, Biology, Physics

FDA Grants Breakthrough Designation for Datar Cancer Genetics Early-Stage Prostate Cancer Detection Blood Test prnewswire.com FDA Grants Breakthrough Designation for Datar Cancer Genetics Early-Stage Prostate Cancer Detection Blood Test Datar Cancer Genetics 3–4 minutes BOSTON , Feb. 14, 2022 /PRNewswire/ -- Datar Cancer Genetics Inc today announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its 'TriNetra-Prostate ™ ' blood test to detect early-stage prostate cancer. This is the second test from the Company that has received the Breakthrough Device Designation from the US FDA. Last year, the Company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation. US FDA Grants the Coveted Breakthrough Designation for Early-Stage Prostate Cancer Detect

New highly accurate blood test gives hope doctors will soon be able to screen for prostate cancer | Daily Mail Online dailymail.co.uk New highly accurate blood test gives hope doctors will soon be able to screen for prostate cancer Martyn Halle, Stephen Adams 3–4 minutes Doctors hail prostate cancer breakthrough as new highly accurate blood test gives hope they will soon be able to screen for the disease Almost one in eight men in Britain will develop prostate cancer in their lives Read more:  New blood test 92% accurate at spotting signs of prostate cancer   Updated: 19:53 EST, 25 February 2023 A new highly accurate blood test for prostate cancer is giving doctors hope that they will soon be able to screen for the disease. Almost one in eight men in Britain will develop prostate cancer in their lives

MacroGenics' Lorigerlimab Shows Promise In Metastatic Prostate Cancer Treatment (NASDAQ:MGNX) | Seeking Alpha

Prospective role of 3βHSD1 in prostate cancer precision medicine - Zhuang - The Prostate - Wiley Online Library

Quality of life outcomes for patients with metastatic castration‐resistant prostate cancer and pretreatment prognostic score - Oyenuga - The Prostate - Wiley Online Library

Prostate Cancer Subgroup May Benefit From Intensified Therapy

Targeting a single enzyme can kill prostate cancer cells news-medical.net Targeting a single enzyme can kill prostate cancer cells Reviewed by Emily Henderson, B.Sc.Feb 3 2023 4–5 minutes For the first time, researchers have discovered that prostate cancer can be killed by targeting a single enzyme, called PI5P4Kα. The findings, published recently in Science Advances , could help address the growing threat of treatment resistance in prostate cancer and could also lead to improved treatments for other cancers, such as those affecting the breast, skin, and pancreas. This is the first time this enzyme has been implicated in prostate cancer, and we expect that it will prove relevant to other cancers as well. An important element of improving precision medicine is using as many tools as possible to treat cancer while mitigating the risk of resistance." Brooke Emerlin

Locally sourced: site-specific immune barriers to metastasis | Nature Reviews Immunology Perspective Published: 07 February 2023 Locally sourced: site-specific immune barriers to metastasis Ana Luísa Correia   Nature Reviews Immunology ( 2023 ) Cite this article Abstract Tumour cells migrate very early from primary sites to distant sites, and yet metastases often take years to manifest themselves clinically or never even surface within a patient’s lifetime. This pause in cancer progression emphasizes the existence of barriers that constrain the growth of disseminated tumour cells (DTCs) at distant sites. Although

New diagnostic test is 1,000 times more sensitive than conventional tests phys.org New diagnostic test is 1,000 times more sensitive than conventional tests Shawn Ballard 9–11 minutes Plasmon-enhanced LFAs (p-LFAs) improve inexpensive, readily available rapid tests to levels of sensitivity required by physicians for confidence in test results without the need for lab-based confirmation. Credit: Singamaneni lab, Washington University in St. Louis When Srikanth Singamaneni and Guy Genin, both professors of mechanical engineering and materials science at the McKelvey School of Engineering at Washington University in St. Louis, established a new collaboration with researchers from the School of Medicine in late 2019, they didn't know the landscape of infectious disease research was about to shift